These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29361690)

  • 41. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Aust D; Bruno MJ; Büchler MW; Delpero JR; Gloor B; Glynne-Jones R; Hartwig W; Huguet F; Laurent-Puig P; Lordick F; Maisonneuve P; Mayerle J; Martignoni M; Neoptolemos J; Rhim AD; Schmied BM; Seufferlein T; Werner J; van Laethem JL; Otto F
    Eur J Cancer; 2017 Jul; 79():41-49. PubMed ID: 28460245
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease.
    Tsai S; Christians KK; Ritch PS; George B; Khan AH; Erickson B; Evans DB
    J Oncol Pract; 2016 Oct; 12(10):915-923. PubMed ID: 27858562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of borderline resectable pancreatic adenocarcinoma.
    Jia Y; Wang TJ; Allendorf J; Saif MW
    JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
    Goff SL; Chabot JA
    Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Borderline resectable pancreatic cancer. Challenges and controversies.
    Sabater L; Muñoz E; Roselló S; Dorcaratto D; Garcés-Albir M; Huerta M; Roda D; Gómez-Mateo MC; Ferrández-Izquierdo A; Darder A; Cervantes A
    Cancer Treat Rev; 2018 Jul; 68():124-135. PubMed ID: 29957372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy].
    Rau HG; Wichmann MW; Wilkowski R; Heinemann V; Sackmann M; Helmberger T; Dühmke E; Schildberg FW
    Chirurg; 2002 Feb; 73(2):132-7. PubMed ID: 11974476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
    Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
    Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant therapy for resectable pancreatic cancer.
    Rahman SH; Urquhart R; Molinari M
    World J Gastrointest Oncol; 2017 Dec; 9(12):457-465. PubMed ID: 29290916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
    Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?
    Kim HJ; Czischke K; Brennan MF; Conlon KC
    J Gastrointest Surg; 2002; 6(5):763-9. PubMed ID: 12399067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?
    Nitsche U; Kong B; Balmert A; Friess H; Kleeff J
    Indian J Med Paediatr Oncol; 2016; 37(4):211-213. PubMed ID: 28144084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.
    Palmarocchi MC; Balzarotti Canger RC; Saletti P
    Oncol Lett; 2017 Jun; 13(6):4445-4452. PubMed ID: 28588713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
    Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
    Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Current consensus and controversy in neoadjuvant therapy for pancreatic cancer].
    Ou ZL; Li YX; Ji LD; Ke MJ
    Zhonghua Wai Ke Za Zhi; 2020 Feb; 58(2):99-104. PubMed ID: 32074807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Surgery for Pancreatic Cancer after neoadjuvant treatment.
    Hackert T
    Ann Gastroenterol Surg; 2018 Nov; 2(6):413-418. PubMed ID: 30460344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions.
    Brunner M; Wu Z; Krautz C; Pilarsky C; Grützmann R; Weber GF
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy.
    Mikulic D; Mrzljak A
    World J Clin Cases; 2021 Jul; 9(20):5398-5407. PubMed ID: 34307593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.